{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:31:59Z","timestamp":1793338319213,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T00:00:00Z","timestamp":1543017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10549-018-5057-7","type":"journal-article","created":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T02:23:55Z","timestamp":1543026235000},"page":"39-45","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE)"],"prefix":"10.1007","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8851-7968","authenticated-orcid":false,"given":"Danielle A.","family":"Henry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Almanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Boulware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Laronga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,24]]},"reference":[{"key":"5057_CR1","unstructured":"PDQ Adult Treatment Editorial Board (2018) PDQ\u00ae Breast Cancer Treatment. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26389406\n                    \n                  . Accessed 14 Apr 2018"},{"key":"5057_CR2","doi-asserted-by":"publisher","unstructured":"American Cancer Society (2018) Cancer Facts & Figs. 2018. \n                    https:\/\/doi.org\/10.3322\/caac.21442","DOI":"10.3322\/caac.21442"},{"key":"5057_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.soc.2017.08.003","volume":"27","author":"B Powers","year":"2018","unstructured":"Powers B, Pal T, Laronga C (2018) Considerations in testing for inherited breast cancer predisposition in the era of personalized medicine. Surg Oncol Clin N Am 27:1\u201322. \n                    https:\/\/doi.org\/10.1016\/j.soc.2017.08.003","journal-title":"Surg Oncol Clin N Am"},{"key":"5057_CR4","unstructured":"Genetic\/Familial High-Risk Assessment (2018): Breast and Ovarian. In: NCCN Clin. Pract. Guidel. Oncol. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf\n                    \n                  . Accessed 3 Feb 2018"},{"key":"5057_CR5","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1126\/science.278.5340.1050","volume":"278","author":"B Ponder","year":"1997","unstructured":"Ponder B (1997) Genetic testing for cancer risk. Science 278:1050\u20131054. \n                    https:\/\/doi.org\/10.1126\/SCIENCE.278.5340.1050","journal-title":"Science"},{"key":"5057_CR6","unstructured":"PDQ\u00ae Cancer Genetics Editorial Board PDQ Genetics of Breast and Gynecologic Cancers (2018): Health Professional Version. In: Bethesda, MD Natl. Cancer Institute. \n                    https:\/\/www.cancer.gov\/types\/breast\/hp\/breast-ovarian-genetics-pdq\n                    \n                  . Accessed 3 Feb 2018"},{"key":"5057_CR7","unstructured":"American Cancer Society (2017) Breast Cancer Facts & Figs. 2017\u20132018"},{"key":"5057_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676\u2013689","journal-title":"Am J Hum Genet"},{"key":"5057_CR9","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1200\/JCO.1996.14.5.1730","volume":"14","author":"American Society of Clinical Oncology","year":"1996","unstructured":"American Society of Clinical Oncology (1996) Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 14:1730\u20131736","journal-title":"J Clin Oncol"},{"key":"5057_CR10","unstructured":"Supreme Court of the United States (2013) Association for molecular pathology et al. v. Myriad Genetics, Inc. \n                    https:\/\/www.supremecourt.gov\/opinions\/12pdf\/12-398_1b7d.pdf\n                    \n                  . Accessed 20 Apr 2018"},{"key":"5057_CR11","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, Van\u2019t Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE study group. J Clin Oncol 22:1055\u20131062. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.04.188","journal-title":"J Clin Oncol"},{"key":"5057_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0826-5","author":"TJ Padamsee","year":"2017","unstructured":"Padamsee TJ, Wills CE, Yee LD, Paskett ED (2017) Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res. \n                    https:\/\/doi.org\/10.1186\/s13058-017-0826-5","journal-title":"Breast Cancer Res"},{"key":"5057_CR13","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF, Evans DG, Henry T, Isaacs C, Garber JE, Neuhausen SL, Matloff E (2010) Europe PMC Funders Group Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967\u2013975. \n                    https:\/\/doi.org\/10.1001\/jama.2010.1237","journal-title":"JAMA"},{"key":"5057_CR14","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/annonc\/mdt134","volume":"24","author":"BAM Heemskerk-Gerritsen","year":"2013","unstructured":"Heemskerk-Gerritsen BAM, Menke-Pluijmers MBE, Jager A, Tilanus-Linthorst MMA, Koppert LB, Obdeijn IMA, van Deurzen CHM, Collee JM, Seynaeve C, Hooning MJ (2013) Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol 24:2029\u20132035. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdt134","journal-title":"Ann Oncol"},{"key":"5057_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002748.pub4","author":"C Ne","year":"2018","unstructured":"Ne C, Lostumbo L, Wallace J, Ko H, Carbine NE, Lostumbo L, Wallace J, Ko H (2018) Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev doi. \n                    https:\/\/doi.org\/10.1002\/14651858.CD002748.pub4","journal-title":"Cochrane Database Syst Rev doi"},{"key":"5057_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1056\/NEJM199901143400201","volume":"340","author":"LC Hartmann","year":"1999","unstructured":"Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Grant CS, Michels VV, Jenkins RB (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77\u201384. \n                    https:\/\/doi.org\/10.1056\/NEJM199901143400201","journal-title":"N Engl J Med"},{"key":"5057_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10549-013-2765-x","volume":"142","author":"SL Ingham","year":"2013","unstructured":"Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo F, Buchan I, Howell A, Evans DGR (2013) Risk-reducing surgery increases survival in BRCA1\/2 mutation carriers unaffected at time of family referral. Breast Cancer Res Treat 142:611\u2013618. \n                    https:\/\/doi.org\/10.1007\/s10549-013-2765-x","journal-title":"Breast Cancer Res Treat"},{"key":"5057_CR18","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1245\/s10434-014-3906-0","volume":"21","author":"D Euhus","year":"2014","unstructured":"Euhus D (2014) Genetic testing today. Ann Surg Oncol 21:3209\u20133215. \n                    https:\/\/doi.org\/10.1245\/s10434-014-3906-0","journal-title":"Ann Surg Oncol"},{"key":"5057_CR19","doi-asserted-by":"publisher","unstructured":"Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA, American Cancer Society Breast Cancer Advisory Group American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75\u201389. \n                    https:\/\/doi.org\/10.3322\/canjclin.57.2.75","DOI":"10.3322\/canjclin.57.2.75"},{"key":"5057_CR20","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1200\/JCO.2009.23.0839","volume":"28","author":"C Kuhl","year":"2010","unstructured":"Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, K\u00f6nig R, Tombach B, Leutner C, Rieber-Brambs A, Nordhoff D, Heindel W, Reiser M, Schild HH (2010) Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 28:1450\u20131457. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.23.0839","journal-title":"J Clin Oncol"},{"key":"5057_CR21","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","volume":"29","author":"E Warner","year":"2011","unstructured":"Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, Foulkes WD, Ghadirian P, Lynch H, Couch F, Wong J, Wright F, Sun P, Narod SA (2011) Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29:1664\u20131669. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.27.0835","journal-title":"J Clin Oncol"},{"key":"5057_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/bjc.2012.204","volume":"107","author":"K Passaperuma","year":"2012","unstructured":"Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA (2012) Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 107:24\u201330. \n                    https:\/\/doi.org\/10.1038\/bjc.2012.204","journal-title":"Br J Cancer"},{"key":"5057_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1399-0004.2009.01329.x","volume":"77","author":"A-B Skytte","year":"2010","unstructured":"Skytte A-B, Gerdes A-M, Andersen MK, Sunde L, Br\u00f8ndum-Nielsen K, Waldstr\u00f8m M, K\u00f8lvraa S, Cr\u00fcger D (2010) Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet 77:342\u2013349. \n                    https:\/\/doi.org\/10.1111\/j.1399-0004.2009.01329.x","journal-title":"Clin Genet"},{"key":"5057_CR24","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1245\/s10434-017-5976-2","volume":"24","author":"E Gilbert","year":"2017","unstructured":"Gilbert E, Zabor EC, Stempel M, Mangino D, Heerdt A, Pilewskie M (2017) Differences Among a modern cohort of BRCA mutation carriers choosing bilateral prophylactic mastectomies compared to breast surveillance. Ann Surg Oncol 24:3048\u20133054. \n                    https:\/\/doi.org\/10.1245\/s10434-017-5976-2","journal-title":"Ann Surg Oncol"},{"key":"5057_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s10549-011-1941-0","volume":"133","author":"KA Metcalfe","year":"2012","unstructured":"Metcalfe KA, Mian N, Enmore M, Poll A, Llacuachaqui M, Nanda S, Sun P, Hughes KS, Narod SA (2012) Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Breast Cancer Res Treat 133:735\u2013740. \n                    https:\/\/doi.org\/10.1007\/s10549-011-1941-0","journal-title":"Breast Cancer Res Treat"},{"key":"5057_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10689-011-9484-4","volume":"11","author":"P Pujol","year":"2012","unstructured":"Pujol P, Lasset C, Berthet P, Dugast C, Delaloge S, Fricker J-P, Tennevet I, Chabbert-Buffet N, This P, Baudry K, Lemonnier J, Roca L, Mijonnet S, Gesta P, Chiesa J, Dreyfus H, Vennin P, Delnatte C, Bignon YJ, Lortholary A, Prieur F, Gladieff L, Lesur A, Clough KB, Nogues C, Martin A-L, French Federation of Cancer Centres (FNCLCC) (2012) Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1\/2 mutations carriers: the LIBER trial. Fam Cancer 11:77\u201384. \n                    https:\/\/doi.org\/10.1007\/s10689-011-9484-4","journal-title":"Fam Cancer"},{"key":"5057_CR27","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/cncr.26294","volume":"118","author":"MD Schwartz","year":"2012","unstructured":"Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L (2012) Long-term outcomes of BRCA1\/BRCA2 testing: risk reduction and surveillance. Cancer 118:510\u2013517. \n                    https:\/\/doi.org\/10.1002\/cncr.26294","journal-title":"Cancer"},{"key":"5057_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1006\/pmed.2000.0684","volume":"31","author":"C Lerman","year":"2000","unstructured":"Lerman C, Hughes C, Croyle RT, Main D, Durham C, Snyder C, Bonney A, Lynch JF, Narod SA, Lynch HT (2000) Prophylactic surgery decisions and surveillance practices one year following BRCA1\/2 testing. Prev Med (Baltim) 31:75\u201380. \n                    https:\/\/doi.org\/10.1006\/pmed.2000.0684","journal-title":"Prev Med (Baltim)"},{"key":"5057_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.amjsurg.2016.06.010","volume":"212","author":"KK Ludwig","year":"2016","unstructured":"Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL (2016) Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review - full. Am J Surg 212:660\u2013669. \n                    https:\/\/doi.org\/10.1016\/j.amjsurg.2016.06.010","journal-title":"Am J Surg"},{"key":"5057_CR30","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1399-0004.2008.00988.x","volume":"73","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe KA, Foulkes WD, Kim-Sing C, Ainsworth P, Rosen B, Armel S, Poll A, Eisen A, Gilchrist D, Chudley A, Ghadirian P, Maugard C, Lemire EG, Sun P, Narod SA (2008) Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet 73:474\u2013479. \n                    https:\/\/doi.org\/10.1111\/j.1399-0004.2008.00988.x","journal-title":"Clin Genet"},{"key":"5057_CR31","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3816\/CBC.2007.n.053","volume":"7","author":"TM Friebel","year":"2007","unstructured":"Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR (2007) Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer 7:875\u2013882. \n                    https:\/\/doi.org\/10.3816\/CBC.2007.n.053","journal-title":"Clin Breast Cancer"},{"key":"5057_CR32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ygyno.2017.02.032","volume":"145","author":"J McGee","year":"2017","unstructured":"McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA (2017) Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: is preventive mastectomy warranted? Gynecol Oncol 145:346\u2013351. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.032","journal-title":"Gynecol Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-5057-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-018-5057-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-5057-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T19:07:35Z","timestamp":1574536055000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-018-5057-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,24]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["5057"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-5057-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,24]]},"assertion":[{"value":"7 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. C. Laronga is on the Speaker\u2019s Bureau at Genomic Health and receives royalties from Up-To-Date. Drs. D. Henry, M. Lee, K. Ahmed and W. Sun, Mr. Boulware, and Ms. Almanza have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}